References
- Kaufman SS, Gondolesi GE, Fishbein TM. Parenteral nutrition associated liver disease. Semin Neonatal 2003;8:375–81
- Titelbaum DH. Parenteral nutrition-associated cholestasis. Curr Opin Pediatr 1997;9:270–5
- Al Tawil Y, Berseth CL. Gestational and postnatal maturation of duodenal motor responses to intragastric feeding. Journal Pediatr 1996;129:374–811
- Peeters TL, Mattijs G, De poortere I, et al. Erythromycin is a motilin receptor agonist. Am J Physiol 1989;257:470–4
- Brunton LL, Lazo JS, Parker KL. Protein synthesis inhibitors and miscellaneous antibacterial agents. In: Goodman and Gilman's, eds. 11th ed. The pharmacological basis of therapeutics. McGraw Hill Medical Publishing Division 2006:1173–202
- Peeters TL. Agonist effect of erythromycin and its analogues on motilin receptors. A new family of prokinetics? Clinical interest. Acta Gastroenterol Belg 1993;56:257–60
- The international neonatal network. The CRIB (clinical risk index for babies) score: a tool for assessing initial neonatal risk and comparing performance of neonatal intensive careunits. Lancet 1993;342:193–8
- Daniel H, Teitelbaum MD. Parenteral nutrition-associated cholestasis. Curr Opin Pediatr 1997;9:270–5
- Aly H, Abdel-Hady H, Khashaba M, El-Badry N. Erythromycin and feeding intolerance in premature infants: a randomized trial. J Perinatol 2007;27:39–43
- Gokmen T, Oguz SS, Bozdag S, et al. A controlled trial of erythromycin and UDCA in premature infants during parenteral nutrition in minimizing feeding intolerance and liver function abnormalities. J Perinatol 2012;32:123–8
- Guay DR, Patterson DR, Seipman N, Craft JC. Overview of the tolerability profile of clarithromycin in preclinical and clinical trials. Drug Saf 1993;8:350–64
- Dhote R, Bergmann JF, Leglise P, et al. Orocecal transit time in humans assessed by sulfapyridine appearance in saliva after sulfasalazine intake. Clin Pharmacol Ther 1995;57:461–70
- Caride VJ, Prokop EK, Troncale FJ, et al. Scintigraphic determination of small intestinal transit time: comparison with the hydrogen breath test. Gastroenterology 1984;86:714–20
- Shobha JC, Koneru A, Naidu MUR. Evaluation of prokinetic action of clarithromycin using orocecal transit time in healthy human subjects. The Internet Journal of Gastroenterology 2009;7:342–8
- Bortolotti M, Mari C, Brunelli F, et al. Effect of intravenous clarithromycin on interdigestive gastroduodenal motility of patients with functional dypepsia and Helicobacter pylori gastritis. Dig Dis Sci 1999;44:2439–42
- Sengupta S, Modak P, McCauley N, O’Donnell LJD. Effect of oral clarithromycin on gall-bladder motility in normal subjects and those with gall-stones. Aliment Pharmacol The 2006;24:95–9
- Itoh Z, Takahashi I. Periodic contraction of the canine gallbladder during the interdigestive state. Am J Physiol 1981;240:183–9
- Rees WDW, Malagelada JR, Miller JL, et al. Human interdigestive and postprandial gastrointestinal motor and gastrointestinal hormonal patterns. Dig Dis Sci 1982;27:321–9
- Kubota M, Nakamura T, Motokura T, et al. Erythromycin improves gastrointestinal motility in extremely low birth weight infants. Acta Pediatr Jpn 1994;36:198–201
- Ng PC, So KW, Fung KS, et al. Randomised controlled study of oral erythromycin for treatment of gastrointestinal dysmotility in preterm infants. Arch Dis Child Fetal Neonatal Ed 2001;84:177–82